drugset / Trial / NCT04045665

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.

Timeline

Start
2019-12-13
Primary completion
2026-08-31
Completion
2026-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule Oral
Subject Dabigatran Unknown Oral
Subject Edoxaban Small molecule Oral
Subject Rivaroxaban Other / unclassified Oral
Background Aspirin Small molecule
Background Clopidogrel Small molecule
Background Ticagrelor Small molecule